Bavarian Nordic sells its Priority Review Voucher for $160M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Bavarian Nordic's PRV Sale: Bavarian Nordic is selling its Priority Review Voucher for $160 million, which was awarded after the FDA approved its chikungunya vaccine, VIMKUNYA. The National Institutes of Health will receive 20% of the sale proceeds.
Financial Impact and Review: The sale will be recorded as other operating income, positively affecting EBITDA, while the transaction is subject to an antitrust review expected in Q3 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
